Pakistan’s Push for Local Vaccine Manufacturing Gains Momentum

Pakistan is moving forward with ambitious plans to produce vaccines locally by 2030, aiming to reduce dependence on imports and strengthen its health security. Health Minister Syed Mustafa Kamal announced that the government is actively pursuing collaborations with Saudi Arabia, Indonesia, and China to achieve this milestone.

Talks with a Saudi delegation last week marked a significant step toward a potential agreement that would allow Pakistan to manufacture vaccines domestically. The delegation, led by senior adviser Nizar Al-Hariri, met with Pakistani health officials to explore partnership opportunities.

Currently, Pakistan imports all 13 vaccines used in its national immunization campaigns, at an annual cost of around $400 million. Nearly half of this expense is covered by international partners, but that support is expected to end after 2030. This looming challenge has prompted the government to accelerate efforts for self-sufficiency.

Minister Kamal emphasized that Pakistan has the capacity to produce raw materials for these vaccines and could eventually export them once local production begins. He described the initiative as being pursued on a “war footing,” highlighting the urgency of building industrial capacity before external funding runs out.

The government is exploring both government-to-government and business-to-business collaborations to ensure success. By partnering with countries that already have advanced vaccine industries, Pakistan hopes to gain technical expertise, investment, and infrastructure support.

This strategy reflects a broader vision: to secure Pakistan’s healthcare future, reduce reliance on imports, and position the country as a regional hub for vaccine production. If successful, the initiative will not only safeguard public health but also open new economic opportunities through exports.

The coming years will be critical as Pakistan works to finalize agreements and build the infrastructure needed to meet its 2030 target. The collaboration with Saudi Arabia, Indonesia, and China could prove pivotal in reshaping the nation’s healthcare landscape.